WO2019105060A1 - 锰型高稳定性超氧化物歧化酶的应用 - Google Patents
锰型高稳定性超氧化物歧化酶的应用 Download PDFInfo
- Publication number
- WO2019105060A1 WO2019105060A1 PCT/CN2018/099148 CN2018099148W WO2019105060A1 WO 2019105060 A1 WO2019105060 A1 WO 2019105060A1 CN 2018099148 W CN2018099148 W CN 2018099148W WO 2019105060 A1 WO2019105060 A1 WO 2019105060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sod
- fatty liver
- use according
- liver
- manganese
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Definitions
- the invention belongs to the fields of biomedicine, functional food and the like, and particularly relates to the application of a superoxide dismutase.
- the fatty liver is alcoholic fatty liver or nonalcoholic fatty liver.
- the medicament is administered by the oral, injection or gavage route.
- the injection is intravenous or intraperitoneal.
- the pharmaceutical dosage form is a tablet, a capsule, a powder, an injection or an aerosol.
- the manganese type high stability superoxide dismutase provided by the invention can effectively reduce the superoxide level, and is suitable for various types of fatty liver such as alcoholic fatty liver, nonalcoholic fatty liver, fatty liver accompanied by metabolic syndrome. Have a good therapeutic effect.
- Figure 3A shows the weight comparison between the high fat diet group and the MS-SOD treatment group
- Figure 4A shows plasma ethanol concentration
- Figure 4B shows liver alcohol dehydrogenase (Adh1) and cytochrome P4502E1 (Cyp2e1) mRNA levels;
- Figure 5D is a fatty liver score
- FIG. 5G shows the results of a glucose tolerance test (GTT).
- Figure 5K shows plasma endotoxin lipopolysaccharide levels.
- High-fat+MS-SOD group (HFD+MS-SOD): fed with high-fat diet for 18 weeks, and starting from the 8th week, the mice were given MS-SOD for 3U/g body weight. Each 0.1ml, once a day, up to 18 weeks. MS-SOD was from the article of Example 1 above.
- High fat feed component add lard based on low fat feed.
- Mn-SOD manganese-type superoxide dismutase
- CuZn-SOD copper-zinc superoxide dismutase
- the test was carried out using the superoxide detection kit of Shanghai Biyuntian Biotechnology Co., Ltd. Kit principle: The superoxide can be detected by using superoxide to reduce the water-soluble tetrazolium-1 (WST-1) to produce soluble colored substances.
- WST-1 water-soluble tetrazolium-1
- MS-SOD gavage group the mice were intragastrically administered orally (oral) at a dose of 6 U/g body weight per day, and the amount of gavage was 0.1 ml per day, once a day for 7 days;
- MS-SOD intraperitoneal injection group mice were intraperitoneally injected with 6 U/g body weight per day, the injection volume was 0.1 ml per time, 1 time/day, and continuous injection for 7 days.
- mice Sixty-five-year-old male C57 mice (purchased from the Guangdong Experimental Animal Center) were housed in an SPF environment and divided into three groups:
- Control group The Lieber-DeCarli alcohol-free liquid diet for 9 weeks;
- Model control group (alcohol, Alc): The Lieber-DeCarli alcoholic liquid diet for 9 weeks;
- MS-SOD treatment group (Alc+SOD): The Lieber-DeCarli alcoholic liquid diet for 9 weeks, while gavage MS-SOD (3 U/g body weight).
- the MS-SOD treatment group was intragastrically administered with MS-SOD solution (3 U/g body weight), the amount of gastric perfusion was 0.1 ml per time, once per day, and the gavage period was 9 weeks.
- the blank control group and the model control group were intragastrically administrated with sterile water, and the amount, frequency and cycle of gavage were the same as those in the treatment group.
- fresh feces were collected every 9 am at 9 am and stored at -80 °C.
- the plasma ALT/AST levels were monitored by eyelid blood collection.
- the tissues were dissected and frozen at -80 °C.
- mice were induced for eight weeks in the diet of liber DeCarli. Ethanol metabolism is not affected by MS-SOD, such as plasma ethanol levels and liver alcohol dehydrogenase, cytochrome p4502E1 expression ( Figures 4A, 4B).
- MS-SOD such as plasma ethanol levels and liver alcohol dehydrogenase, cytochrome p4502E1 expression
- the liver weight/body weight ratio was significantly higher in the alcohol group and slightly lower in the alcohol + SOD group (Fig. 4C).
- plasma alanine aminotransferase levels were significantly reduced in the alcohol + SOD group (Fig. 4D).
- hepatic lipid accumulation and liver ccl2 expression were significantly reduced in the MS-SOD group (Fig. 4E-H).
- MS-SOD can improve the symptoms of intestinal flora imbalance, intestinal leakage and hepatic steatosis caused by alcohol feeding.
- Example 6 MS-SOD alleviates the symptoms of fatty liver and metabolic syndrome in mouse genetically deleted leptin (ob/ob mice)
- ITT Insulin tolerance test
- MS-SOD treatment significantly changed the composition of the intestinal flora (Fig. 5I).
- Fig. 5I By monitoring the levels of fecal albumin and plasma endotoxin lipopolysaccharide, it was found that MS-SOD significantly improved intestinal leakage and translocation of bacterial products (Fig. 5J, K).
- MS-SOD relieves the symptoms of fatty liver and metabolic disorders in the OB/OB mouse model.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
- 锰型高稳定性超氧化物歧化酶在制备治疗脂肪肝的药物中的应用,其中,所述锰型高稳定性超氧化物歧化酶的氨基酸序列如SEQ ID NO:4所示。
- 根据权利要求1所述的应用,其中,所述脂肪肝为酒精性脂肪肝或非酒精性脂肪肝。
- 根据权利要求1或2所述的应用,其中,所述脂肪肝为伴有代谢综合征的脂肪肝。
- 根据权利要求3所述的应用,其中,所述代谢综合征为高血糖或者胰岛素抵抗。
- 根据权利要求1-4任一项所述的应用,其中,所述药物为口服、注射或灌胃途径给药。
- 根据权利要求5所述的应用,其中,所述注射为静脉注射或腹腔注射。
- 根据权利要求1-4任一项所述的应用,其中,所述药物剂型为片剂、胶囊剂、粉针、注射剂或气雾剂。
- 根据权利要求1-4任一项所述的应用,其中,所述药物还包括一种或多种制药学上可接受的辅料。
- 根据权利要求8所述的应用,其中,所述辅料为稀释剂、粘合剂、润湿剂、崩解剂、溶剂和/或缓冲剂。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/615,140 US20200155652A1 (en) | 2017-11-29 | 2018-08-07 | Use of manganese superoxide dismutase with high stability |
JP2019545313A JP6822705B2 (ja) | 2017-11-29 | 2018-08-07 | 安定性の高いマンガンスーパーオキシドジスムターゼの使用 |
EP18884034.2A EP3581198B1 (en) | 2017-11-29 | 2018-08-07 | Manganese-type high-stability superoxide dismutase for use in treating fatty liver |
KR1020197034625A KR20190138874A (ko) | 2017-11-29 | 2018-08-07 | 높은 안정성을 가진 망가니즈 수퍼옥시드 디스뮤타제의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711228830.X | 2017-11-29 | ||
CN201711228830.XA CN107823635A (zh) | 2017-11-29 | 2017-11-29 | 锰型高稳定性超氧化物歧化酶的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019105060A1 true WO2019105060A1 (zh) | 2019-06-06 |
Family
ID=61646631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/099148 WO2019105060A1 (zh) | 2017-11-29 | 2018-08-07 | 锰型高稳定性超氧化物歧化酶的应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200155652A1 (zh) |
EP (1) | EP3581198B1 (zh) |
JP (1) | JP6822705B2 (zh) |
KR (1) | KR20190138874A (zh) |
CN (1) | CN107823635A (zh) |
WO (1) | WO2019105060A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107823635A (zh) * | 2017-11-29 | 2018-03-23 | 杭州睿道医药科技有限公司 | 锰型高稳定性超氧化物歧化酶的应用 |
CN109276711B (zh) * | 2018-10-18 | 2022-04-05 | 杭州睿道医药科技有限公司 | 锰型高稳定性超氧化物歧化酶在改善自闭症中的应用及产品 |
CN110872581B (zh) * | 2019-12-03 | 2022-07-22 | 苏州大学 | 一种耐高温、带ptd的突变型sod和应用 |
CN112891521A (zh) * | 2019-12-04 | 2021-06-04 | 凯睿恒济生物医药(杭州)有限公司 | 锰型高稳定性超氧化物歧化酶在脑卒中预防或治疗中的应用 |
CN112725295A (zh) * | 2020-05-27 | 2021-04-30 | 浙江工业大学 | 一种重组型超氧化物歧化酶及其编码基因和制备方法 |
CN113797322A (zh) * | 2020-06-12 | 2021-12-17 | 凯睿恒济生物医药(杭州)有限公司 | 锰型高稳定性超氧化物歧化酶在糖尿病预防或治疗中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035095A1 (en) * | 2001-10-19 | 2003-05-01 | Maxim Pharmaceuticals, Inc. | Use of histamine to treat liver disease |
CN103446165A (zh) * | 2013-09-12 | 2013-12-18 | 中国海洋大学 | 低聚古罗糖醛酸在制备预防和治疗酒精性肝损伤的药物、保健品或饮食补充剂中的应用 |
CN103505720A (zh) * | 2012-06-30 | 2014-01-15 | 复旦大学 | 载脂蛋白a-i在制备预防和治疗肝病代谢综合征药物中的用途 |
CN107823635A (zh) * | 2017-11-29 | 2018-03-23 | 杭州睿道医药科技有限公司 | 锰型高稳定性超氧化物歧化酶的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130058993A1 (en) * | 2011-09-01 | 2013-03-07 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhancing wound healing using car peptides |
CN103223161A (zh) * | 2013-05-13 | 2013-07-31 | 甘肃省人民医院 | 锰超氧化物歧化酶模拟物在制备保肝药物中的应用 |
CN105624126B (zh) * | 2016-02-23 | 2017-02-01 | 杭州睿道医药科技有限公司 | 一种新型重组高稳定性超氧化物歧化酶及其应用 |
-
2017
- 2017-11-29 CN CN201711228830.XA patent/CN107823635A/zh active Pending
-
2018
- 2018-08-07 WO PCT/CN2018/099148 patent/WO2019105060A1/zh unknown
- 2018-08-07 KR KR1020197034625A patent/KR20190138874A/ko not_active Application Discontinuation
- 2018-08-07 JP JP2019545313A patent/JP6822705B2/ja active Active
- 2018-08-07 US US16/615,140 patent/US20200155652A1/en not_active Abandoned
- 2018-08-07 EP EP18884034.2A patent/EP3581198B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035095A1 (en) * | 2001-10-19 | 2003-05-01 | Maxim Pharmaceuticals, Inc. | Use of histamine to treat liver disease |
CN103505720A (zh) * | 2012-06-30 | 2014-01-15 | 复旦大学 | 载脂蛋白a-i在制备预防和治疗肝病代谢综合征药物中的用途 |
CN103446165A (zh) * | 2013-09-12 | 2013-12-18 | 中国海洋大学 | 低聚古罗糖醛酸在制备预防和治疗酒精性肝损伤的药物、保健品或饮食补充剂中的应用 |
CN107823635A (zh) * | 2017-11-29 | 2018-03-23 | 杭州睿道医药科技有限公司 | 锰型高稳定性超氧化物歧化酶的应用 |
Non-Patent Citations (1)
Title |
---|
"Principles and Clinical Applications of Glucose Tolerance Test", SHANGHAI MED J., vol. 32, no. 5, 2009, pages 440 - 443 |
Also Published As
Publication number | Publication date |
---|---|
EP3581198A4 (en) | 2020-08-12 |
KR20190138874A (ko) | 2019-12-16 |
CN107823635A (zh) | 2018-03-23 |
US20200155652A1 (en) | 2020-05-21 |
EP3581198B1 (en) | 2022-03-30 |
EP3581198A1 (en) | 2019-12-18 |
JP6822705B2 (ja) | 2021-01-27 |
JP2020516585A (ja) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019105060A1 (zh) | 锰型高稳定性超氧化物歧化酶的应用 | |
US12036251B2 (en) | Strain for preventing and treating metabolic diseases and use thereof | |
JP2018532779A (ja) | 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル | |
JP5554994B2 (ja) | 乳酸菌含有製剤 | |
KR20210014576A (ko) | 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 그의 예방 또는 치료용 약학적 조성물 | |
Zhang et al. | Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study | |
WO2024041604A1 (zh) | 酸奶衍生多肽在制备延缓端粒缩短药物及抗衰老药物中的应用 | |
CN114245743B (zh) | 预防、缓解或治疗肝损伤的组合物和方法 | |
CN109943622B (zh) | 亚硝基谷胱甘肽还原酶的医药用途 | |
US20220257669A1 (en) | Composition and method for preventing, alleviating, or treating liver injury | |
KR102122903B1 (ko) | 블라우티아 속 세균 유래 나노소포 및 이의 용도 | |
WO2018027898A1 (zh) | 一种产丁酸栖粪杆菌及其培养方法和应用 | |
CN107961382B (zh) | miR-1252在制备治疗特应性皮炎的药物中的应用 | |
JP2008239500A (ja) | レプチン分泌促進剤 | |
CN106619591B (zh) | 奥昔卡因在制备药物中的用途及药物组合物 | |
EP4349350A1 (en) | Bacterial strain, composition, drug for use in combination, and use | |
TWI740101B (zh) | 降膽固醇之益生菌株的用途 | |
CN114681492B (zh) | 改善代谢性疾病的肠道益生菌及其应用 | |
US20220325323A1 (en) | Skin microbiome monitoring for improving systemic health | |
CN105797132A (zh) | 沙奎拉韦的医药新用途 | |
CN105902544A (zh) | 阿扎那韦的医药新用途 | |
CN105748471A (zh) | 利托那韦的医药新用途 | |
KR101870012B1 (ko) | Tis21의 발현조절제를 유효성분으로 포함하는 비알콜성 지방간 예방 또는 치료용 조성물 | |
Yao et al. | Hyperbaric Oxygen Therapy Inhibits Neuronal Ferroptosis After Spinal Cord Injury in Mice | |
TWI609691B (zh) | 台灣冬蟲夏草在第一型糖尿病及其併發症上的醫藥用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18884034 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019545313 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018884034 Country of ref document: EP Effective date: 20190829 |
|
ENP | Entry into the national phase |
Ref document number: 20197034625 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |